Establishment of a method for selecting antimicrobial agents and determining their early efficacy using blood substances from patients with bacteremia.

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K16439
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Gunma University
• Principal Investigator: Yashima Hideaki 群馬大学, 大学院医学系研究科, 助教 (60773512)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 抗菌薬 / 緑膿菌 / 迅速検査 / 効果判定 / プロテオーム解析 / メロペネム

Outline of Final Research Achievements

In this study, I detected several proteins altered when Pseudomonas aeruginosa was exposed to antimicrobial agents. In particular, 16 proteins whose expression rates differed significantly by more than 10-fold or less than 1/10 depending on the antimicrobial susceptibility were considered to be promising marker candidates for determining efficacy. In the future, I will examine the correlation of these candidate marker proteins with drug susceptibility in different P. aeruginosa strains and their detection sensitivity in the blood, and I expect to establish markers that will enable us to determine the efficacy of antimicrobial agents against Pseudomonas aeruginosa.

Free Research Field

医療薬学

Academic Significance and Societal Importance of the Research Achievements

本研究では緑膿菌の抗菌薬に対する効果判定を可能とするマーカー候補を検出することができたが、このマーカーが患者の血液検体から検出可能なマーカーとして使用できるようになった場合、病院内で高頻度かつ耐性化が問題となっている緑膿菌による感染症の抗菌薬治療の迅速な効果判定が可能となると考えられる。それにより感染初期に多剤耐性菌を発見でき、適切な薬剤選択が可能となることから治療成績の向上が見込まれる。